PATOLOŠKO KRVARENJE IZ MATERICE KOD ŽENA U REPRODUKTIVNOM PERIODU
Sažetak
Uvod: Patološko krvarenje iz materice predstavlja jedan od najčešćih poremećaja zdravlja kod žena u reproduktivnom periodu. Uz to, predstavlja i značajan javno-zdravstveni problem. Cilj ovog rada je da se prikaže savremena podela, kao i osnovi dijagnostike i lečenja patoloških krvarenja iz materice.
Metode: U radu su prikazani podaci iz radova selektovanih pretraživanjem MEDLINE baze korišćenjem kombinacije ključnih reči: “menstrual bleeding”, “abnormal uterine bleeding”, “PALM-COEIN classification”, “leiomyoma”, “endometrial polyp”, “adenomyosis”, “gynecological malignancies”, “coagulopathy”, “diagnostics of abnormal uterine bleeding”, i “treatment of abnormal uterine bleeding”. Podaci prikupljeni iz odabranih radova upotrebljeni su i predstavljeni u ovom radu.
Zaključak: U cilju postizanja jedinstvene klasifikacije poremećaja menstrualnog ciklusa, usvojena je klasifikacija ovih poremećaja koja se naziva akronimom PALM-COEIN. Uzroci nabrojani u prvom delu kronima (PALM) imaju patološko-anatomski supstrat na nivou genitalnih organa koji se može dijagnostikovati primenom imidžing metoda i/ili histopatološkim pregledom. Uzroci nabrojani u drugom delu akronima (COEIN) uključuju difsunkcionalne poremećaje i ne mogu se dijagnostikovati primenom imidžing metoda.
Reference
[1] Munro MG, Critchley HOD, Fraser IS. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil Steril 2011;95:2204-2208.e3. https://doi.org/10.1016/j.fertnstert.2011.03.079.
[2] Spremovic-Radjenovic S, Stefanovic A, Kadija S, Jeremic K, Sparic R. Classification and the diagnostics of abnormal uterine bleeding in nongravid women of reproductive age: The PALM-COEIN classification system adopted by the International Federation of Gynecology and Obstetrics. Vojnosanit Pregl 2016;73:1154–9. https://doi.org/10.2298/VSP160709289S.
[3] Munro MG, Critchley HOD, Fraser IS. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynecol Obstet 2018;143:393–408. https://doi.org/10.1002/ijgo.12666.
[4] Marnach ML, Laughlin-Tommaso SK. Evaluation and Management of Abnormal Uterine Bleeding. Mayo Clin Proc 2019;94:326–35. https://doi.org/10.1016/j.mayocp.2018.12.012.
[5] Munro MG. Practical aspects of the two FIGO systems for management of abnormal uterine bleeding in the reproductive years. Best Pract Res Clin Obstet Gynaecol 2017;40:3–22. https://doi.org/10.1016/j.bpobgyn.2016.09.011.
[6] Liu Z, Doan QV., Blumenthal P, Dubois RW. A Systematic Review Evaluating Health-Related Quality of Life, Work Impairment, and Health-Care Costs and Utilization in Abnormal Uterine Bleeding. Value Heal 2007;10:183–94. https://doi.org/10.1111/j.1524-4733.2007.00168.x.
[7] Sparic R, Mirkovic L, Malvasi A, Tinelli A. Epidemiology of uterine myomas: A review. Int J Fertil Steril 2016;9:424–35. https://doi.org/10.22074/ijfs.2015.4599.
[8] Nijkang NP, Anderson L, Markham R, Manconi F. Endometrial polyps: Pathogenesis, sequelae and treatment. SAGE Open Med 2019;7:205031211984824. https://doi.org/10.1177/2050312119848247.
[9] Salim S, Won H, Nesbitt-Hawes E, Campbell N, Abbott J. Diagnosis and Management of Endometrial Polyps: A Critical Review of the Literature. J Minim Invasive Gynecol 2011;18:569–81. https://doi.org/10.1016/j.jmig.2011.05.018.
[10] Leyendecker G, Kunz G, Herbertz M, Beil D, Huppert P, Mall G, et al. Uterine Peristaltic Activity and the Development of Endometriosis. Ann N Y Acad Sci 2004;1034:338–55. https://doi.org/10.1196/annals.1335.036.
[11] de Bruijn AM, Smink M, Lohle PNM, Huirne JAF, Twisk JWR, Wong C, et al. Uterine Artery Embolization for the Treatment of Adenomyosis: A Systematic Review and Meta-Analysis. J Vasc Interv Radiol 2017;28:1629-1642.e1. https://doi.org/10.1016/j.jvir.2017.07.034.
[12] Laughlin SK, Stewart EA. Uterine Leiomyomas. Obstet Gynecol 2011;117:396–403. https://doi.org/10.1097/AOG.0b013e31820780e3.
[13] Sparić R. Uterine myomas in pregnancy, childbirth and puerperium. Srp Arh Celok Lek 2014;142:118–24. https://doi.org/10.2298/SARH1402118S.
[14] Tinelli A, Vinciguerra M, Malvasi A, Andjić M, Babović I, Sparić R. Uterine Fibroids and Diet. Int J Environ Res Public Health 2021;18:1066. https://doi.org/10.3390/ijerph18031066.
[15] Tinelli A, Resta L, Sparić R, Stefanović A, Malvasi A. Pathogenesis, Classification, Histopathology, and Symptomatology of Fibroids. Uterine Fibroids, Cham: Springer International Publishing; 2018, p. 1–47. https://doi.org/10.1007/978-3-319-58780-6_1.
[16] Tinelli A, Sparić R, Kadija S, Babović I, Tinelli R, Mynbaev OA, et al. Myomas: Anatomy and related issues. Minerva Ginecol 2016;68:261–73.
[17] Sparic R, Terzic M, Malvasi A, Tinelli A. Uterine fibroids - clinical presentation and complications. Acta Chir Iugosl 2014;61:41–8. https://doi.org/10.2298/ACI1403041S.
[18] Sparic R, Nejkovic L, Mutavdzic D, Malvasi A, Tinelli A. Conservative surgical treatment of uterine fibroids. Acta Chir Iugosl 2014;61:11–6. https://doi.org/10.2298/ACI1404011S.
[19] Gupta S, Jose J, Manyonda I. Clinical presentation of fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:615–26. https://doi.org/10.1016/j.bpobgyn.2008.01.008.
[20] Manyonda I, Belli A-M, Lumsden M-A, Moss J, McKinnon W, Middleton LJ, et al. Uterine-Artery Embolization or Myomectomy for Uterine Fibroids. N Engl J Med 2020;383:440–51. https://doi.org/10.1056/NEJMoa1914735.
[21] See ATA, Havenga S. Outcomes of women with postcoital bleeding. Int J Gynecol Obstet 2013;120:88–9. https://doi.org/10.1016/j.ijgo.2012.07.017.
[22] Doraiswami S, Johnson T, Rao S, Rajkumar A, Vijayaraghavan J, Panicker VK. Study of Endometrial Pathology in Abnormal Uterine Bleeding. J Obstet Gynecol India 2011;61:426–30. https://doi.org/10.1007/s13224-011-0047-2.
[23] Haidopoulos D, Simou M, Akrivos N, Rodolakis A, Vlachos G, Fotiou S, et al. Risk factors in women 40 years of age and younger with endometrial carcinoma. Acta Obstet Gynecol Scand 2010;89:1326–30. https://doi.org/10.3109/00016349.2010.515666.
[24] James AH, Manco-Johnson MJ, Yawn BP, Dietrich JE, Nichols WL. Von Willebrand Disease. Obstet Gynecol 2009;114:674–8. https://doi.org/10.1097/AOG.0b013e3181b191ea.
[25] Deligeoroglou E, Karountzos V. Abnormal Uterine Bleeding including coagulopathies and other menstrual disorders. Best Pract Res Clin Obstet Gynaecol 2018;48:51–61. https://doi.org/10.1016/j.bpobgyn.2017.08.016.
[26] Elmaoğulları S, Aycan Z. Abnormal Uterine Bleeding In Adolescents. J Clin Res Pediatr Endocrinol 2018;10:191–7. https://doi.org/10.4274/jcrpe.0014.
[27] Thakur M, Maharjan M, Tuladhar H, Dwa Y, Bhandari S, Maskey S, et al. Thyroid Dysfunction in Patients with Abnormal Uterine Bleeding in a Tertiary Care Hospital: A Descriptive Cross-sectional Study. J Nepal Med Assoc 2020;58. https://doi.org/10.31729/jnma.5033.
[28] Delitala AP, Capobianco G, Delitala G, Cherchi PL, Dessole S. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Arch Gynecol Obstet 2017;296:405–19. https://doi.org/10.1007/s00404-017-4429-2.
[29] Joffe H, Hayes FJ. Menstrual Cycle Dysfunction Associated with Neurologic and Psychiatric Disorders. Ann N Y Acad Sci 2008;1135:219–29. https://doi.org/10.1196/annals.1429.030.
[30] McCarthy KJ, Gollub EL, Ralph L, van de Wijgert J, Jones HE. Hormonal Contraceptives and the Acquisition of Sexually Transmitted Infections: An Updated Systematic Review. Sex Transm Dis 2019;46:290–6. https://doi.org/10.1097/OLQ.0000000000000975.
[31] Parkash V, Fadare O, Tornos C, McCluggage WG. Committee Opinion No. 631: Endometrial Intraepithelial Neoplasia. Obstet Gynecol 2015;126:897. https://doi.org/10.1097/AOG.0000000000001071.
